Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative...
28 insider purchases on record · latest filing 2024-09-03.
Insiders have also filed 2 sale transactions at QNCX.